Cabaletta Bio Inc Dossier
Qualitative Analysis
Business overview
Cabaletta Bio, Inc. (NASDAQ: CABA) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of engineered T-cell therapies for patients with autoimmune diseases. The company's proprietary CABA platform encompasses two primary strategies: CARTA (Chimeric Antigen Receptor T cells for Autoimmunity) and CAART (Chimeric Autoantibody Receptor T cells). Its lead product candidate is resecabtagene autoleucel (rese-cel, formerly CABA-201), a fully human CD19-directed CAR T-cell therapy being evaluated across multiple autoimmune indications, including systemic lupus erythematosus (SLE), lupus nephritis (LN), myositis, systemic sclerosis (SSc), and pemphigus vulgaris (PV).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing resecabtagene autoleucel (rese-cel, formerly CABA-201), a fully human CD19-directed CAR-T cell therapy, across multiple autoimmune indications including myositis, systemic sclerosis, lupus, and myasthenia gravis.
Expected impact: Aims to deliver deep, durable, and potentially curative drug-free clinical responses for patients with severe autoimmune diseases.
Developing and evaluating a preconditioning-free dosing regimen for rese-cel to eliminate the need for chemotherapy (fludarabine/cyclophosphamide) prior to CAR-T infusion.
Expected impact: Improves patient and provider experience, accelerates outpatient adoption, and significantly expands the commercial market opportunity.
Transitioning the manufacturing of rese-cel to automated platforms to scale up clinical and commercial supply capabilities while lowering per-batch costs.
Expected impact: Enables the scalable production of thousands of cell therapy batches per year at among the lowest cost of goods in the industry.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
A 10-year commercial supply agreement signed in April 2026 to manufacture rese-cel using Cellares' automated Cell Shuttle and planned Cell Q platforms. This secures high-throughput, low-cost autologous cell therapy manufacturing capabilities to support clinical development and future commercial launch.
Terms: Aims for among the lowest per-batch costs in autologous cell therapy with minimal capital investment.
A CDMO arrangement expanded in January 2025 to supply clinical-grade rese-cel under current Good Manufacturing Practices (cGMP) to support ongoing clinical trials.
Terms: Not disclosed